19 reports

MARKET ##.

  • Chronic Disease
  • Diagnostics
  • DNA
  • Canada
  • Company Financials

This agreement enables One Lambda and TSI to access Molecular Microscope Diagnostic System.

  • Allergy
  • Chronic Disease
  • Canada
  • Forecast
  • QIAGEN N.V.

One unit equals to one test.

  • Chronic Disease
  • Medical Device
  • Canada
  • Forecast
  • SQI Diagnostics Inc.
  • HEART FAILURE GENOMICS RISK TEST - PRODUCT STATUS
  • HEART FAILURE RISK STRATIFICATION TEST - PRODUCT STATUS

CardioGenics provides immunoassay tests such as heart failure genomics risk test, heart failure risk stratification test, plasminogen activator inhibitor type-## test, and troponin I test.

  • Chronic Disease
  • Medical Device
  • Canada
  • Litigation And Patent
  • CardioGenics Holdings Inc.
  • Business Description
  • Deal in Brief

Each unit is consists of one common share and one-half of one share purchase warrant.

  • Chronic Disease
  • Medical Device
  • Medical Equipment
  • Canada
  • Company
  • PROOF CENTRE ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH ALLERGEN FOR ALLERGY BIOMARKERS

GlobalData The Centre of Excellence for Prevention of Organ Failure' s, deal volume decreased from one medical equipment deal in 2016 to zero medical equipment deals in 2017.

  • Chronic Disease
  • Medical Device
  • Canada
  • United States
  • Deals & Alliance
  • Key facts
  • Deal status

Each unit consists of one common share and one half of one common share purchase warrant.

  • Chronic Disease
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Canada

Everist Genomics Inc, Deals By Market, 2011 to YTD 2017 Market Cardiovascular Devices In Vitro Diagnostics Medical Equipment Distributors No. of Deals ## ## ## Note: Deals include all announced medical equipment deals from 2011 onwards, deal values included wherever disclosed.

  • Chronic Disease
  • Medical Equipment
  • Canada
  • Deals & Alliance
  • Everist Genomics, Inc.
  • Key facts
  • Deal status

Each unit consists of one common share and one half of one common share purchase warrant.

  • Chronic Disease
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Canada

HAS ACQUIRED A ##% STAKE IN PATHOGEN REMOVAL AND DIAGNOSTIC TECHNOLOGIES, INC.

  • Chronic Disease
  • Healthcare
  • Pharmaceutical
  • Canada
  • ProMetic Life Sciences Inc.
  • Deal status

PARTNER ##: CEAPRO INC.

  • Chronic Disease
  • Pharmaceutical
  • Canada
  • Company
  • Ceapro Inc.
  • MIRACULINS INC. COMPANY OVERVIEW
  • Indication

Clinical Trials by Trial Status Trial Status No of Clinical Trials Colorectal Cancer ## Coronary Artery Disease ## Diabetes Mellitus ## Gastric Cancer ## Pancreatic Cancer ## Preeclampsia ## Prostate Cancer ## Ongoing, not Recruiting

  • Chronic Disease
  • Colorectal Cancer
  • Diabetes
  • Canada
  • Miraculins Inc.

PARTNER ##: ANGES MG, INC.

  • Chronic Disease
  • Hospital
  • Canada
  • Corporate Finance
  • Mitsubishi Corporation

HAS ACQUIRED A ##% STAKE IN PATHOGEN REMOVAL AND DIAGNOSTIC TECHNOLOGIES, INC.

  • Chronic Disease
  • Healthcare
  • Pharmaceutical
  • Canada
  • ProMetic Life Sciences Inc.

Company type Business description COMPANY INFORMATION: PARTNERS PARTNER ##: INNOVATIVE TARGETING SOLUTIONS, INC.

  • Chronic Disease
  • Immunology
  • Pharmaceutical
  • Canada
  • Zymeworks Inc.

The company offers a wide range of aluminium-free allergy vaccines and diagnostics.

  • Allergy Drug
  • Chronic Disease
  • Therapy
  • Canada
  • Pfizer Inc.

PARTNER ##: ANGES MG, INC.

  • Chronic Disease
  • Hospital
  • Canada
  • Corporate Finance
  • Mitsubishi Corporation

The company' s core pharmaceuticals product business consists of three categories, namely, Prescription Drugs, OTC Drugs and Diagnostics.

  • Allergy Drug
  • Chronic Disease
  • Therapy
  • Canada
  • Pfizer Inc.

Its products include Probiotics ADR-##, Probiotics AAP-##, Probiotics GM##, Probiotics DHA-##/ DHC-##/ DHS-##, Probiotics CLR-## and others.

  • Allergy Drug
  • Chronic Disease
  • Therapy
  • Canada
  • Pfizer Inc.